Dr. Lal Path Labs Ltd.
General Updates
01 / The disclosure
What the company shared
Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates
A question for your research
Read the underlying filing for the complete disclosure and any conditions not included in the exchange summary.
The evidence
Read the source excerpts
01Sub: Update on Acquisition of stake in SN Genelab Private Limited Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”)
Page 1
02With reference to the captioned subject and in continuation to our earlier intimation dated September 24, 2026, wherein we have informed that the Board of Directors of the Company has approved for acquisition of stake in SN Genelab Private Limited (“SN Gene”).
Page 1
03We wish to inform you that the Company has completed the said acquisition on October 01, 2026, as per the terms and conditions of the Agreement.
Page 1
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- 106805533
- First collected
- 3 Oct 2026, 17:17 IST
- PDF extraction
- extracted · 1 pages read
- Extraction note
- Source excerpts; financial tables have not been validated.
- Document SHA-256
- c3765043feda054fd2cfa029c78a03eb941240911eb344a3f8e4e5bf4038cc5d